Aurobindo Pharma Limited on January 1, 2026 informed stock exchanges that its wholly owned subsidiary, Auro Pharma Limited, has approved the acquisition of the non-oncology prescription formulations business of Khandelwal Laboratories Private Limited. The transaction has been executed on a going-concern basis through a Business Transfer Agreement.
According to the disclosure filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, the acquisition covers Khandelwal’s branded non-oncology prescription formulations business, including inventory, intellectual property, employees, contracts and related infrastructure, on a slump-sale basis. No equity shares or control of Khandelwal Laboratories are being acquired as part of the transaction.
The acquired business comprises 23 brands marketed across 67 SKUs, along with nine pipeline products. Anti-infectives and pain management form the core portfolios of the business. It reported a turnover of ₹1,135.3 million in FY 2024-25 with an EBITDA of ₹289.9 million.
The business also brings with it a field force of around 470 personnel and an extensive distribution network with more than 1,600 stockists across India. Khandelwal Laboratories operates in both oncology and non-oncology segments, though only the non-oncology prescription formulations business is part of this acquisition.
Aurobindo Pharma stated that the acquisition is not a related-party transaction and that neither the promoter nor the promoter group has any interest in the business being acquired. The transaction does not require any governmental or regulatory approvals.
The consideration for the acquisition is entirely in cash, amounting to ₹3,250 million, subject to working capital adjustments as outlined in the definitive agreements. The transaction was signed and closed on January 1, 2026, and is effective from the same date.
The company said the acquisition will strengthen its domestic pharmaceutical presence by adding new brands in pain management and anti-infective therapies, complementing its existing product portfolio and supporting further expansion in the Indian market.
The non-oncology business being acquired has been operating in the Indian pharmaceutical market since 1973-74. Over the past three financial years, it recorded revenues of ₹1,049.8 million in FY 2022-23, ₹1,146.9 million in FY 2023-24 and ₹1,135.3 million in FY 2024-25, with operations limited to India.
